Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 366 of 1,261
  1. US 10912746

    Methods and compositions for treating conditions associated with an abnormal inflammatory response

    First Wave Bio, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  2. US 10912771

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  3. US 10912770

    Targeting AMP deaminase 2 for ameliorating craving for sugar and other substances

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  4. US 10912797

    Tumor infiltrating lymphocytes and methods of therapy

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  5. US 10913957

    Genetically modified MSC and therapeutic methods

    The Regents of the University of California · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  6. US 10913785

    Anti-human papillomavirus 16 E6 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  7. US 10912783

    Formulations for solubilizing hormones

    Compass Therapeutics LLC · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  8. US 10913709

    STAT3 inhibitor formulation

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  9. US 10912779

    Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

    Asana BioSciences, LLC · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  10. US 10912767

    Anthracycline prodrugs and methods of making and using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  11. US 10912776

    Methods of treating cancer

    Corvus Pharmaceuticals, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  12. US 10913753

    Thienopyridine carboxamides as ubiquitin-specific protease inhibitors

    Valo Early Discovery, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  13. US 10912741

    Prevention of liver cancer with safranal-based formulations

    UNITED ARAB EMIRATES UNIVERSITY · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  14. US 10912764

    Salinosporamides and methods of use thereof

    The Regents of the University of California · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  15. US 10912754

    Methods and compositions for treating excessive sleepiness

    Jazz Pharmaceuticals Ireland Limited · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  16. US 10912751

    Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

    Esperion Therapeutics, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  17. US 10912860

    Controllable self-annealing microgel particles for biomedical applications

    The Regents of the University of California · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  18. US 10913950

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  19. US 10913948

    RNA interference in dermal and fibrotic indications

    Phio Pharmaceuticals Corp. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  20. US 10913947

    Antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  21. US 10913946

    RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy

    BIOMARIN TECHNOLOGIES B.V. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  22. US 10913790

    Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  23. US 10913888

    Nanotube mediation of degradative chemicals for oil-field application

    MOLECULAR REBAR DESIGN, LLC · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  24. US 10913798

    Modulators of ROR1-ROR2 binding

    The Regents of the University of California · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.